Confirmatory studies to support accelerated approval of Merck & Co., Inc.’s Keytruda (pembrolizumab) and Bristol Myers Squibb Company’s Opdivo (nivolumab) did not demonstrate a clinical benefit for second-line treatment of hepatocellular carcinoma, but the companies may be able to retain the indication at least until additional studies are completed.
At its 29 April meeting, the FDA’s Oncologic Drugs Advisory Committee will consider whether Keytruda and Opdivo can maintain the...





